These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 24580023)

  • 1. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years.
    Conry JA; Ng YT; Kernitsky L; Mitchell WG; Veidemanis R; Drummond R; Isojarvi J; Lee D; Paolicchi JM;
    Epilepsia; 2014 Apr; 55(4):558-67. PubMed ID: 24580023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clobazam is efficacious for patients across the spectrum of disease severity of Lennox-Gastaut syndrome: post hoc analyses of clinical trial results by baseline seizure-frequency quartiles and VNS experience.
    Wheless JW; Isojarvi J; Lee D; Drummond R; Benbadis SR
    Epilepsy Behav; 2014 Dec; 41():47-52. PubMed ID: 25282105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome.
    Ng YT; Conry JA; Drummond R; Stolle J; Weinberg MA;
    Neurology; 2011 Oct; 77(15):1473-81. PubMed ID: 21956725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clobazam : in patients with Lennox-Gastaut syndrome.
    Yang LP; Scott LJ
    CNS Drugs; 2012 Nov; 26(11):983-91. PubMed ID: 23034582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing clobazam treatment in patients with Lennox-Gastaut syndrome.
    Isojarvi J; Gidal BE; Chung S; Wechsler RT
    Epilepsy Behav; 2018 Jan; 78():149-154. PubMed ID: 29202277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study.
    Ng YT; Conry J; Paolicchi J; Kernitsky L; Mitchell W; Drummond R; Isojarvi J; Lee D; Owen R;
    Epilepsy Behav; 2012 Dec; 25(4):687-94. PubMed ID: 23141144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deconstructing tolerance with clobazam: Post hoc analyses from an open-label extension study.
    Gidal BE; Wechsler RT; Sankar R; Montouris GD; White HS; Cloyd JC; Kane MC; Peng G; Tworek DM; Shen V; Isojarvi J
    Neurology; 2016 Oct; 87(17):1806-1812. PubMed ID: 27683846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Withdrawal-related adverse events from clinical trials of clobazam in Lennox-Gastaut syndrome.
    Tolbert D; Harris SI; Bekersky I; Lee D; Isojarvi J
    Epilepsy Behav; 2014 Aug; 37():11-5. PubMed ID: 24949576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term use of clobazam in Lennox-Gastaut syndrome: experience in a single tertiary epilepsy center.
    Lee EH; Yum MS; Choi HW; Ko TS
    Clin Neuropharmacol; 2013; 36(1):4-7. PubMed ID: 23334068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budget impact analysis of antiepileptic drugs for Lennox-Gastaut syndrome.
    Skornicki M; Clements KM; O'Sullivan AK
    J Manag Care Spec Pharm; 2014 Apr; 20(4):400-6. PubMed ID: 24684645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clobazam-treated patients with Lennox-Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012.
    Isojarvi J; Lee D; Peng G; Sperling MR
    Epilepsia; 2016 Jun; 57(6):e113-6. PubMed ID: 27145465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clobazam is equally safe and efficacious for seizures associated with Lennox-Gastaut syndrome across different age groups: Post hoc analyses of short- and long-term clinical trial results.
    Ng YT; Conry J; Mitchell WG; Buchhalter J; Isojarvi J; Lee D; Drummond R; Chung S
    Epilepsy Behav; 2015 May; 46():221-6. PubMed ID: 25940107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.
    Knupp KG; Scheffer IE; Ceulemans B; Sullivan J; Nickels KC; Lagae L; Guerrini R; Zuberi SM; Nabbout R; Riney K; Agarwal A; Lock M; Dai D; Farfel GM; Galer BS; Gammaitoni AR; Polega S; Davis R; Gil-Nagel A
    Epilepsia; 2023 Jan; 64(1):139-151. PubMed ID: 36196777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rufinamide: a pharmacoeconomic profile of its use as adjunctive therapy in Lennox-Gastaut syndrome.
    McCormack PL
    Pharmacoeconomics; 2012 Mar; 30(3):247-56. PubMed ID: 22332960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox-Gastaut syndrome.
    Clements KM; Skornicki M; O'Sullivan AK
    Epilepsy Behav; 2013 Oct; 29(1):184-9. PubMed ID: 23973644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome.
    Cramer JA; Sapin C; François C
    Acta Neurol Scand; 2013 Aug; 128(2):91-9. PubMed ID: 23410109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA).
    Hahn CD; Jiang Y; Villanueva V; Zolnowska M; Arkilo D; Hsiao S; Asgharnejad M; Dlugos D
    Epilepsia; 2022 Oct; 63(10):2671-2683. PubMed ID: 35841234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clobazam for patients with Lennox-Gastaut syndrome and epilepsy.
    Seif-Eddeine H; Ng YT
    Expert Rev Neurother; 2012 Apr; 12(4):385-93. PubMed ID: 22449211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
    Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K;
    Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.